Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
about
Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesComparison of molecular serotyping approaches of Streptococcus agalactiae from genomic sequences.Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine DevelopmentReal-time PCR-based serotyping of Streptococcus agalactiaeMaternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Immunization During Pregnancy: Impact on the Infant.Screening for early-onset invasive group B Streptococcal disease in neonates in an Irish hospital (2001-2014): a retrospective audit.Group B streptococcal PCR testing in comparison to culture for diagnosis of late onset bacteraemia and meningitis in infants aged 7-90 days: a multi-centre diagnostic accuracy study.Vaccination of HIV-infected pregnant women: implications for protection of their young infants.Colonization prevalence and antibiotic susceptibility of Group B Streptococcus in pregnant women over a 6-year period in Dongguan, China.Neonatal protection and preterm birth reduction following maternal group B streptococcus vaccination in a mouse model.Immunization with a Latch Peptide Provides Serotype-Independent Protection against Group B Streptococcus Infection in Mice.Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy.Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.Epidemiology of invasive group B streptococcal disease in infants from urban area of South China, 2011-2014.Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001-2015.Clinical and laboratory features of Group B Streptococcus meningitis in infants and newborns: study of 848 cases in France from 2001-2014.Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models.Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.Current Challenges and Achievements in Maternal Immunization Research.Development of experimental GBS vaccine for mucosal immunization.Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review.The Impact of IgG transplacental transfer on early life immunityPerinatal Streptococcus agalactiae Epidemiology and Surveillance TargetsMaternal group B Streptococcus recto vaginal colonization increases the odds of stillbirth: evidence from Eastern EthiopiaExperience and challenges on influenza and pertussis vaccination in pregnant womenMaternal immunisation: What have been the gains? Where are the gaps? What does the future hold?
P2860
Q28075884-BB26898D-8392-489A-8181-CDE04E134C91Q33755860-54C1B543-1A89-4CE4-A51A-A84B28D84670Q36236399-04E35F7B-C961-4C4C-8377-C9C5B2D3A957Q37464437-9989F298-2C39-4452-BD95-BC29D8993E90Q38649517-BFEAA2BD-46EC-406F-B06E-47B1C861A839Q38683189-98C4DAFE-3CB7-4B62-8C5D-F509D5E9F844Q38918659-A5D7CCF8-DDD4-42E6-9098-1FD94739C627Q39155676-D61C8429-7267-4391-AE0D-523463036DE7Q40051928-41D5E132-0449-41E4-BE6F-6E49D2A34E00Q40091480-8AE16C93-3AB6-481F-9FA4-A8AFF75493DFQ40410171-B16C6C36-C2C9-48B4-8088-E8A42329CDCFQ45934269-7A5A2742-8610-43BC-8D8B-77A3A0FADC2AQ46470356-7027EAC8-1D83-4B3D-B1EC-6715FDB4E693Q46954965-B846A639-1523-4818-94A1-F1D02B38CDB5Q46987999-B6C90E78-B48F-49E6-B668-8A45C7C360C2Q47196377-7F795576-48A8-4E87-A122-D2A2DA14BE64Q47546256-26ED5FA2-5938-468F-8595-5EC18659D0B1Q47767787-668DF84E-28E0-406C-A573-FA17873C02C2Q50129993-361598AE-715B-4630-AE2E-67F703C53CE4Q52624533-9AB97157-0205-4C45-A033-62F9477CE212Q52645927-F515E2C6-36B8-4690-B089-3CE22B8EA045Q55002977-C6865313-3C66-4F26-8402-CB49C6AC78B1Q55314785-94A69C43-CDCA-451E-A209-E42B096FDCB3Q56505186-B14A1DB7-8D15-4F6D-A847-EE717D4B769FQ57169196-335697D1-EC40-4273-A123-A72D0D64F300Q57809525-0C888147-8033-4E2B-9792-6E8BC943FF5EQ57942673-D2B2FB8F-A2D0-4551-A9DB-671E828326D9Q59133818-D0E02932-246E-4222-BF9D-292B0B45A95E
P2860
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Safety and immunogenicity of a ...... a randomised phase 1b/2 trial.
@en
type
label
Safety and immunogenicity of a ...... a randomised phase 1b/2 trial.
@en
prefLabel
Safety and immunogenicity of a ...... a randomised phase 1b/2 trial.
@en
P2093
P1476
Safety and immunogenicity of a ...... a randomised phase 1b/2 trial.
@en
P2093
Ajoke Sobanjo-Ter Meulen
Anthonet Koen
Frederick Wittke
Karen Slobod
Morounfolu Olugbosi
Niresha Govender
Peter M Dull
Sherryl Baker
Vas Narasimhan
P304
P356
10.1016/S1473-3099(16)00152-3
P577
2016-04-29T00:00:00Z